SurveyRole of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition
Introduction
The c-Met receptor tyrosine kinase was originally identified as an oncogene activated in vitro after treatment of a human osteogenic sarcoma (HOS) cell line with a chemical carcinogen N-methyl-N′-nitro-N-nitrosoguanidine [1]. In the HOS cell line, the Met proto-oncogene (chromosome 7) was involved in a translocation that placed the translocated promoter region locus (TPR) on chromosome 1 just upstream of a portion of the Met gene [2]. The TPR–MET fusion protein contained constitutively active Met kinase activity. Isolation of the TPR–MET cDNA led to the identification of the full-length Met receptor. Since this original characterization of c-Met as a proto-oncogene, much has been learned about the normal structure and function of c-Met, and great interest currently surrounds the role of aberrant c-Met signaling in tumorigenesis, particularly in the development of the invasive and metastatic phenotypes.
Met serves as the high affinity receptor for hepatocyte growth factor/scatter factor (HGF/SF), a disulfide-linked heterodimeric molecule produced predominantly by mesenchymal cells and acting primarily on Met-expressing epithelial cells in an endocrine and/or paracrine fashion [3]. HGF/SF is so named because it was identified independently as both a growth factor for hepatocytes and as a fibroblast-derived cell motility factor, or scatter factor. Signaling via the Met–HGF/SF pathway has been shown to lead to an array of cellular responses including proliferation (mitosis), scattering (motility), and branching morphogenesis. The cellular responses to c-Met stimulation by HGF/SF are important in mediating a wide range of biological activities including embryological development, wound healing, tissue regeneration, angiogenesis, growth, invasion, and morphogenic differentiation [4]. As several of these physiological processes are known to go awry during tumorigenesis and metastasis, Met–HGF/SF signaling has been identified to play a role in many human cancers.
c-Met mutations have been well-described in hereditary and sporadic human papillary renal carcinomas and have been reported in ovarian cancer, childhood hepatocellular carcinoma, metastatic head and neck squamous cell carcinomas, and gastric cancer. c-Met is also over-expressed in both non-small cell lung cancer and small cell lung cancer cells. Since c-Met appears to play an important role in oncogenesis of a variety of tumors, various inhibition strategies have been employed to therapeutically target this receptor tyrosine kinase. This review will discuss these topics in detail but in no way is designed to be overall comprehensive. Where also possible for the reader, we have also referred recently published review articles, and apologize if we have not referred the original or other published papers on the subject.
Section snippets
Structure
The human Met (HGF receptor) gene is located on chromosome 7 band 7q21–q31 and spans more than 120 kb in length, consisting of 21 exons separated by 20 introns [5]. In wild-type cells, the primary Met transcript produces a 150 kDa polypeptide that is partially glycosylated to produce a 170 kDa precursor protein. This 170 kDa precursor is further glycosylated and then cleaved into a 50 kDa α-chain and a 140 kDa β-chain which are linked via disulfide bonds.
Met homologs have been found in several
The ligand HGF/SF
Hepatocyte growth factor (HGF) was originally identified as a potent mitogen for hepatocytes and purified as a disulfide-linked heterodimer consisting of a 62-kDa α-subunit and a 34 kDa β-subunit. The α-subunit (heavy) contains an N-terminal hairpin domain consisting of about 27 amino acids followed by four canonical kringle domains, which are 80-amino acid double-looped structures stabilized by three internal disulfide bridges [10], [12], [13]. Kringle domains are important for protein–protein
Alterations of Met–HGF/SF detected in various human cancers
Aberrant c-Met signaling has been described in a variety of human cancers [16]. Mutations in c-Met, over-expression of c-Met and/or HGF/SF, and expression of c-Met and HGF/SF by the same cell can all contribute to tumorigenesis [4], [17], [18]. Cell lines with uncontrolled c-Met activation via one of these mechanisms are both highly invasive and metastatic [4]. Increased c-Met and/or HGF/SF expression by human tumor cells is often associated with high tumor grade and poor prognosis [19]. We
Overview
HGF/SF–Met signaling has been shown to trigger a variety of cellular responses that vary based upon the cellular context. For example, in vitro studies have revealed that activation of c-Met by HGF/SF leads to hepatocyte, renal tubule cell, and endothelial cell proliferation, stimulation of cell dissociation and motility i.e. scattering, and stimulation of cell movement through the extracellular matrix, i.e. invasion [6], [18]. Furthermore, signaling via this pathway has been shown to induce
Signaling via the cytoskeleton
A large signaling complex is recruited to activated c-Met and includes the adapter proteins Grb2, SHC, Gab1, and Crk/CRKL and the signal transducers phosphotidylinositol-3-OH kinase (PI3K), the signal transducer and activator of transcription-3 (Stat3), phospholipase C-γ (PLC-γ), the Ras guanine nucleotide exchange factor son-of-sevenless (SOS), the Src kinase, and the SHP2 phosphatase. Interaction of c-Met with adapter proteins and signal transducers can occur directly via the multisubstrate
Potential inhibitors of the c-Met pathways
Because of the overwhelming evidence favoring the role of aberrant HGF/SF–Met signaling in the pathogenesis of various human cancers, endogenous and exogenous inhibitors of this signaling pathway have drawn much interest. Specific inhibitors may have important therapeutic potential for the treatment of cancers in which Met activity contributes to the invasive/metastatic phenotype. There is a strong precedence to develop inhibitors of receptor tyrosine kinases. Fruitful studies from STI 571
Conclusion
c-Met is a unique receptor tyrosine kinase that plays an important role in the pathogenesis of a variety of malignancies. There are a number of activating mutations identified as well as cancers identified with over-expression of this receptor. With the ligand HGF/SF stimulating c-Met, there are a range of biological effects in tumor cells including scattering, branching morphogenesis, cell motility, invasion, migration and eventual metastasis. The biochemical pathways regulating all of these
Acknowledgements
This work was supported by NIH Grant CA75348-05 and Lowe’s Center for Thoracic Oncology (RS).
References (126)
- et al.
Mechanism of met oncogene activation
Cell
(1986) The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization
Gene
(1998)- et al.
Chicken macrophage stimulating protein is a ligand of the receptor protein–tyrosine kinase Sea
J. Biol. Chem.
(1999) - et al.
Signalling by semaphorin receptors: cell guidance and beyond
Trends Cell Biol.
(2000) - et al.
Plasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growth
Exp. Cell Res.
(1999) - et al.
Frequent amplification of the c-met gene in scirrhous type stomach cancer
Biochem. Biophys. Res. Commun.
(1992) - et al.
Concomitant expression of hepatocyte growth factor (HGF), HGF activator and c-met genes in human glioma cells in vitro
FEBS Lett.
(1995) - et al.
Missense mutation of the MET gene detected in human glioma
Mod. Pathol.
(2000) - et al.
The Met/hepatocyte growth factor receptor (HGFR) gene is over-expressed in some cases of human leukemia and lymphoma
Leuk. Res.
(1994) - et al.
Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease
Blood
(1999)
The clinical significance of hepatocyte growth factor for non-small cell lung cancer
Ann Thorac. Surg.
c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma
Am J. Pathol.
c-met proto-oncogene expression in benign and malignant human prostate tissues
J. Urol.
Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma
Hum. Pathol.
HGF: a multifunctional growth factor controlling cell scattering
Int. J. Biochem. Cell Biol.
The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation
Adv. Cancer Res.
The molecular basis of lung morphogenesis
Mech. Dev.
Involvement of oxidative stress in tumor cytotoxic activity of hepatocyte growth factor/scatter factor
J. Biol. Chem.
Actin-based cell motility and cell locomotion
Cell
Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis
Eur. J. Cancer
Hematopoietic growth factors signal through the formation of reactive oxygen species
Blood
Integrins: versatility, modulation, and signaling in cell adhesion
Cell
Involvement of focal adhesion kinase in hepatocyte growth factor-induced scatter of Madin–Darby canine kidney cells
J. Biol. Chem.
The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant
Biochem. Biophys. Res. Commun.
Differential signaling by the focal adhesion kinase and cell adhesion kinase beta
J. Biol. Chem.
Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells
J. Biol. Chem.
Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL
J. Biol. Chem.
Molecular cloning of a new transforming gene from a chemically transformed human cell line
Nature
Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor–met signalling in human cells concomitant with induction of the urokinase proteolysis network
Mol. Cell Biol.
Activating mutations for the met tyrosine kinase receptor in human cancer
Proc. Natl. Acad. Sci. USA
Met receptor tyrosine kinase: enhanced signaling through adapter proteins
Oncogene
Plexins, semaphorins, and scatter factor receptors: a common root for cell guidance signals?
IUBMB Life
Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family
Science
Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells
Exs.
The HGF receptor family: unconventional signal transducers for invasive cell growth
Genes Cells
Organization of the human hepatocyte growth factor-encoding gene
Gene
Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA
Am. J. Pathol.
Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene
Curr. Drug Targets
Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor
Oncogene
The mutationally activated Met receptor mediates motility and metastasis
Proc. Natl. Acad. Sci. USA
Hepatocyte growth factor/scatter factor–Met signaling in tumorigenicity and invasion/metastasis
J. Mol. Med.
Infrequent mutations of the MET gene in sporadic breast tumours (letter)
Int. J. Cancer
Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma
Cancer
c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma
Histopathology
Over-expression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas
Oncogene.
Clinical significance of c-met oncogene alterations in human colorectal cancer
Oncology
Aberrant expression of c-met mRNA in human gastric carcinomas
Int. J. Cancer
Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas
Apmis
A novel germ line juxtamembrane Met mutation in human gastric cancer
Oncogene
Somatic mutations of the met oncogene are selected during metastatic spread of human HNSC carcinomas
Oncogene
Cited by (371)
Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance
2023, Biomedicine and PharmacotherapyResveratrol, reactive oxygen species, and mesothelioma
2021, Cancer: Oxidative Stress and Dietary AntioxidantsCombinatorial approaches targeting the EGFR family and c-Met in SCCHN
2021, Oral OncologyStructure–activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy
2020, European Journal of Medicinal ChemistryDesign, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors
2020, Bioorganic and Medicinal Chemistry Letters